BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29435063)

  • 1. Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells
    Lu F; Xu H; Wang Q; Li M; Meng J; Kuang Y
    Oncol Lett; 2018 Mar; 15(3):3233-3239. PubMed ID: 29435063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
    Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
    Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
    Kuang Y; Lu F; Guo J; Xu H; Wang Q; Xu C; Zeng L; Yi S
    Onco Targets Ther; 2017; 10():3131-3144. PubMed ID: 28706445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity.
    Huo X; Sun H; Qian Q; Ma X; Peng P; Yu M; Zhang Y; Yang J; Cao D; Gui T; Shen K
    Front Cell Dev Biol; 2020; 8():561804. PubMed ID: 33163485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression.
    Cai C; Peng X; Zhang Y
    Bioengineered; 2021 Dec; 12(1):7007-7019. PubMed ID: 34551671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
    Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
    Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
    Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
    Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 regulates the expression of p16 in the nasopharyngeal cancer cells.
    Zhong J; Min L; Huang H; Li L; Li D; Li J; Ma Z; Dai L
    Technol Cancer Res Treat; 2013 Jun; 12(3):269-74. PubMed ID: 23289480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo.
    Guo J; Cai J; Yu L; Tang H; Chen C; Wang Z
    Cancer Sci; 2011 Mar; 102(3):530-9. PubMed ID: 21205084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.
    Zhang Y; Wang J; An W; Chen C; Wang W; Zhu C; Chen F; Chen H; Zheng W; Gong J
    Technol Cancer Res Treat; 2019; 18():1533033819854132. PubMed ID: 31138033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
    Li Q; Li B; Dong C; Wang Y; Li Q
    Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy.
    Sun Y; Jin L; Liu JH; Sui YX; Han LL; Shen XL
    Cancer Biother Radiopharm; 2016 Sep; 31(7):246-52. PubMed ID: 27610467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.